Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients ; volume:10 ; number:1 ; day:29 ; month:10 ; year:2020 ; pages:1-11 ; date:12.2020
Scientific reports ; 10, Heft 1 (29.10.2020), 1-11, 12.2020
- Creator
-
Marczynski, Gabriella Taques
Laus, Ana Carolina
Reis, Mariana Bisarro dos
Reis, Rui Manuel
Vazquez, Vinicius de Lima
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-020-75792-1
- URN
-
urn:nbn:de:101:1-2020120922420199046598
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:39 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Marczynski, Gabriella Taques
- Laus, Ana Carolina
- Reis, Mariana Bisarro dos
- Reis, Rui Manuel
- Vazquez, Vinicius de Lima
- SpringerLink (Online service)
Other Objects (12)
Circulating Tumour DNA in Melanoma—Clinic Ready?
Detection of metastases using circulating tumour DNA in uveal melanoma
Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report
Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
Circulating tumor DNA in Hodgkin lymphoma
Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp
Circulating tumor DNA is detectable in canine histiocytic sarcoma, oral malignant melanoma, and multicentric lymphoma
Cell-free circulating tumor DNA in cancer
Quantifying circulating cell-free DNA in humans
Circulating Tumour DNA in Melanoma—Clinic Ready?
Detection of metastases using circulating tumour DNA in uveal melanoma
Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report
Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
Circulating tumor DNA in Hodgkin lymphoma
Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp
Circulating tumor DNA is detectable in canine histiocytic sarcoma, oral malignant melanoma, and multicentric lymphoma
Cell-free circulating tumor DNA in cancer
Quantifying circulating cell-free DNA in humans
Circulating Tumour DNA in Melanoma—Clinic Ready?
Detection of metastases using circulating tumour DNA in uveal melanoma
Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report
Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy
Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
Circulating tumor DNA in Hodgkin lymphoma
Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp
Circulating tumor DNA is detectable in canine histiocytic sarcoma, oral malignant melanoma, and multicentric lymphoma
Cell-free circulating tumor DNA in cancer